Preliminary reports from recent phase 2 trials, presented at the 2023 European Society for Medical Oncology (ESMO) and 2024 American Society of Clinical Oncology (ASCO) meetings have shown encouraging pCR rates in patients with HER2-positive resectable G/GEJ adenocarcinoma treated with PD-1 inhibitors plus trastuzumab and chemotherapy [7, 12]. This evidence concerns the gene ERBB2 and adenocarcinoma.